Quarterly Result15 May 2026, 04:51 pm
Gland Pharma Q4FY26: PAT Up 97% YoY, Revenue Up 22%
AI Summary
Gland Pharma Ltd announced its Q4FY26 financial results, reporting a 22% YoY increase in revenue and a 97% YoY increase in adjusted PAT. The company's revenue from operations stood at ₹17,428 million. The Board recommended a final dividend of ₹20 per share. CDMO business contributed 46% of revenues and grew by 36% year-on-year in Q4FY26.
Key Highlights
- Q4FY26 revenue from operations increased by 22% YoY to ₹17,428 million.
- Adjusted PAT for Q4FY26 grew by 97% YoY to ₹3,667 million.
- The Board recommended a final dividend of ₹20 per share.
- CDMO business contributed 46% of revenues and grew by 36% year-on-year in Q4FY26.
- Full year FY26 revenues increased by 14.5%.
Price Impact
More from GLAND